Targeting CTCL with Precision - The Power of IL2 Receptor Therapy

Intervoke is proud to have created this cinematic-quality Mechanism of Action animation for LYMPHIR, an FDA-approved therapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL). Developed by Citius Pharmaceuticals, LYMPHIR is a groundbreaking recombinant fusion protein designed to target both malignant T-cells and immunosuppressive regulatory T-cells (Tregs) by binding to the shared IL-2 receptor, which is present on both cell types.

Once LYMPHIR binds to the IL-2 receptor, it enters the cells and delivers a diphtheria toxin fragment that disrupts protein synthesis, leading to the induction of apoptosis. This powerful mechanism helps eliminate the cancer-driving malignant T-cells and transiently depletes Tregs, ultimately restoring immune balance and empowering the body's immune system to fight the disease more effectively.

This high-impact animation from Intervoke brings the complex science of LYMPHIR to life with exceptional clarity, emotion, and precision. It serves as a valuable educational tool for healthcare professionals and stakeholders, helping them understand the novel mechanism of action behind LYMPHIR and its potential to improve outcomes for patients with CTCL.

Through this animation, Intervoke bridges the gap between innovative pharmaceutical solutions and their understanding in the medical community, enhancing communication and knowledge sharing in the fight against cancer.